Brainstorm cell therapeutics inc. announces the mount sinai medical center as a progressive ms phase 2 clinical trial site

Brainstorm cell therapeutics inc. (brainstorm) announced that the mount sinai medical center, internationally acclaimed for its excellence in research, patient care, and education in multiple sclerosis and across a range of medical specialties, has contracted with brainstorm as a clinical study site for the company’s phase 2 open-label, multicenter study of repeated intrathecal administration of nurown (autologous msc-ntf cells) in participants with progressive multiple sclerosis (ms).
BCLI Ratings Summary
BCLI Quant Ranking